190,623 Shares in MacroGenics Inc (NASDAQ:MGNX) Purchased by Eversept Partners LP
Eversept Partners LP purchased a new position in MacroGenics Inc (NASDAQ:MGNX) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 190,623 shares of the biopharmaceutical company’s stock, valued at approximately $3,235,000. MacroGenics makes up about 0.9% of Eversept Partners LP’s investment portfolio, making the stock its 25th largest holding. Eversept Partners LP owned 0.39% of MacroGenics at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of MGNX. Marshall Wace North America L.P. acquired a new position in MacroGenics in the first quarter worth about $59,000. Marshall Wace LLP bought a new stake in MacroGenics during the first quarter worth approximately $80,000. Bank of Montreal Can raised its holdings in MacroGenics by 804.2% during the first quarter. Bank of Montreal Can now owns 5,000 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 4,447 shares in the last quarter. Quantamental Technologies LLC bought a new stake in MacroGenics during the second quarter worth approximately $122,000. Finally, BNP Paribas Arbitrage SA raised its holdings in MacroGenics by 62,661.5% during the first quarter. BNP Paribas Arbitrage SA now owns 8,159 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 8,146 shares in the last quarter.
Several equities research analysts recently commented on MGNX shares. BidaskClub cut MacroGenics from a “sell” rating to a “strong sell” rating in a report on Friday, July 19th. Zacks Investment Research upgraded shares of MacroGenics from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research report on Wednesday, August 7th. Wedbush reiterated an “outperform” rating and set a $27.00 price objective on shares of MacroGenics in a research report on Thursday, July 18th. ValuEngine cut shares of MacroGenics from a “buy” rating to a “hold” rating in a research report on Monday, July 8th. Finally, Stifel Nicolaus lowered their price objective on shares of MacroGenics from $29.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $30.98.
MacroGenics (NASDAQ:MGNX) last announced its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.96) by $0.31. The business had revenue of $10.59 million during the quarter, compared to analyst estimates of $17.58 million. MacroGenics had a negative net margin of 273.47% and a negative return on equity of 54.52%. Equities analysts anticipate that MacroGenics Inc will post -3.2 EPS for the current fiscal year.
MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.
Featured Article: CD Ladder
Want to see what other hedge funds are holding MGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MacroGenics Inc (NASDAQ:MGNX).
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.